Trevi Therapeutics reports positive results in its Phase 2 trial of the investigational drug Haduvio in patients with idiopathic pulmonary fibrosis who are suffering from chronic cough.
The New Haven-based company indicated it will stop recruiting patients in the trial due to the “strength and consistency of the data.”